Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes

Reviewed by José E. Rodríguez¹ and Kendall M. Campbell²

Study
Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin 2015;31:913–923

Summary
This article is a narrative review of the epidemiological data available on diabetes prevalence and care and of studies indexed in PubMed involving trials that evaluated treatments for type 2 diabetes in racial minority populations. The authors examined data from the Centers for Disease Control and Prevention and from the National Health and Nutrition Examination Survey. Table 1 provides a summary of demographic data (1–7). Because of the difficulties in gathering data for all three large racial and ethnic minorities in the United States, disparities are presented solely for African Americans compared to whites and for Hispanics compared to whites. The prevalence of diagnosed type 2 diabetes by racial/ethnic group is as follows: Asians 9.0%, African Americans 13.2%, Hispanic 12.8%, and non-Hispanic whites 7.6%. There is a wide variation in prevalence in the Native American population (e.g., 6.0% in Alaskan Natives and 24.1% in southern Arizona Native American groups) and among Hispanics (e.g., 8.5% in Central/South Americans, 9.3% in Cubans, 13.9% in Mexican Americans, and 14.8% in Puerto Ricans) (8).

Objective. The purpose of this study was to identify and describe all clinical drug trials for type 2 diabetes that included Asians, African Americans, or Hispanics.

Design. The authors conducted a literature review of studies indexed in MEDLINE and accessed through PubMed.

Methods. The authors searched PubMed using the terms African, African American, Hispanic, Asian, type 2 diabetes, biguanides, sulfonylureas, thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter 2 inhibitors, and individual drugs available in each class. A narrative review of the identified studies (many of which were themselves meta-analyses) was then written.

Results. Nineteen individual drugs and one drug class were tested in Asians, African Americans, or Hispanics (Table 2) (8–28). Four drugs or drug classes were tested in all three populations (Asians, African Americans, and Hispanics) (Table 3). An additional five medications were tested in two of the three populations (Table 4). Of all of the medications or drug classes reported, only four did not include Asian subjects: exenatide extended release, canagliflozin, bromocriptine, and colesvelam. With the exception of colesvelam, these drugs also were not tested in African Americans or Hispanics. It is important to note that the majority
of studies that included Asians were performed in Asian countries (40/75 or 53%).

Commentary
This article was a narrative review of all studies of medications used to treat type 2 diabetes that were studied in Asians, African Americans, or Hispanics. We have chosen for this commentary and recommend to other researchers and authors the use of the terms “Black” and “Latino” rather than “African American” and “Hispanic,” respectively, as preferred terms for these racial/ethnic groups. We recognize that “Black” is an inclusive term for African Americans, Haitian Americans, and other minorities of African descent and that “Latino” is a less inclusive term than “Hispanic,” but more accurately describes this group as underrepresented in medicine (29). Of note, Ferdinand and Nasser did not present any studies of diabetes drugs in Native Americans, the group with the highest racial/ethnicity-specific prevalence of type 2 diabetes that would likely receive the most benefit from glucose-lowering therapies.

Although Asians, Blacks, and Latinos all have a higher prevalence of type 2 diabetes than whites in the United States, only four drugs/drug classes were tested in all three of these populations. These four drugs represent <20% of the available medications for patients with type 2 diabetes. This article does an excellent job of highlighting the racial/ethnic disparities in drug testing. These three populations combined represent >35% (5.3% Asian, 13.2% Black, and 17.1% Latino) of the patient population in the United States, and all three populations have a higher percentage of patients with diabetes than does the white population.

Interestingly, some of the disparities data presented in the introduction of this article give the impression that health disparities are a function of access to care and socioeconomic status, both of which are limited in the U.S. Black and Latino populations. One reviewed study showed that 40–60% of diabetes disparities can be attributed to socioeconomic status alone. However, this figure is controversial and should be considered under advisement. Although the article we are reviewing did not specifically state as much, no discussion of health disparities would be complete without recognition and confrontation of racism in the United States (30). The Institute of Medicine’s 2002 report “Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care” cited racism and stereotyping as major contributors to health disparities (31). Unfortunately, recent current events suggest that racism persists in the United States.

Although there are severe disparities in drug testing, virtually all of the medications mentioned in this review article are used in U.S. Asian, Black, and Latino populations. We would suggest testing in these populations, but because of severe historical abuses by medical researchers (e.g., the Tuskegee Syphilis Experiment and the case of Henrietta Lacks), such testing it may be difficult without close monitoring and regulatory control. However, more studies could be performed with patients who are currently taking these medications. Perhaps more rigorous postmarketing surveillance could be undertaken to elucidate the differing effects of medications in Black, Latino, Asian, and Native American populations.

It is encouraging to see affordable medications being studied in Black and Latino populations. Clinical trials on metformin and sulfonylureas have great significance in these minority groups because these drugs

| TABLE 1. Summary of Disparities Data Presented in the Article Reviewed (1–7) |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Hospitalization rate (%) | 26.5 | — | 16.1 (1) |
| Well-controlled glycemia (%) | 37.6 | — | 44.0 (2) |
| Well-controlled cholesterol (%) | 39.5 | — | 46.8 (2) |
| Well-controlled blood pressure (%) | 29.0 | — | 35.4 (2) |
| Comorbid conditions of abdominal obesity, high blood pressure, elevated triglycerides, and risk of type 2 diabetes (OR) | 9.1 | 4.8 | 2.3 (3) |
| Exercise rates (OR [95% CI]) | 0.65 (0.53–0.80) | 0.34 (0.26–0.45) | [reference] (4) |
| Dilated eye exam (%) | 64 | 55 | 64 (5) |
| Mean A1C increase (%) | −0.65 | −0.5 | [reference] (6) |
| 7-Year incidence of diabetes (%) | +128 | +67 | [reference] (7) |
| Disparity due to socioeconomic status alone (%) | 44.7 | 54.9 | [reference] (7) |

OR, odds ratio.
are inexpensive and usually are easy to access; they are free in certain places and cost only a few dollars per month in others (32). Because of their ease of accessibility, there is less extrapolation and undocumented opinion about the benefits and side effects of these drugs in Blacks and Latinos.

What is more concerning is the paucity of clinical trials of newer diabetes drugs that include Black, Latino, and Native American subjects. These drugs will likely increase in importance as the diabetes epidemic expands. Because diabetes affects minorities at an disproportionate rate, the lack of clinical trials involving these groups may mean more experimentation with newer diabetes drugs in the absence of research evidence of their efficacy and effects. This scenario could lead to adverse events, hospitalizations,

| TABLE 2. Drug Therapies Studies in African-American, Hispanic, or Asian Populations and Included in the Article Reviewed (8–28) |
|---------------------------------|---------------------------------------------------------------------------------------------------------------|
| **Medication**                 | **Observed Racial/Ethnic Difference**                                                                 |
| Sulfonylureas                  | Associated with increased arterial stiffness in African Americans (9)                                       |
| Acarbose                      | Improved glycemic control (A1C reduction of 1.05%) in Asians who were inadequately controlled on a sulfonylurea; not tested in African Americans or Hispanics (10) |
| Voglibose                     | Tested only in Asians and found to be inferior to sitagliptin and dosed more frequently; caused more adverse events without better glycemic lowering (A1C reduction of 0.7% for sitagliptin and 0.3% for voglibose (11)) |
| Miglitol                      | 1.9% reduction in A1C in African Americans (12); 0.26% A1C reduction in Hispanics (13)                        |
| Sitagliptin                   | A1C reductions of 0.9% (14) and 1.0% (15) in Asians; not tested in African Americans and Hispanics             |
| Saxagluptin                   | Studied in African Americans and Hispanics but no subgroup analyses were performed; A1C reduction of 0.84% in Asians with few side effects (16) |
| Linagliptin                   | A1C reductions of 0.63% in Hispanics (17) and 0.58% in African Americans (18)                                |
| Vildaglptin                   | Improved glycemic control in Asians when added to metformin (19)                                           |
| Alogliptin                    | A1C reductions in Japanese patients when added to voglibose (20)                                           |
| Metformin                     | African Americans had better A1C lowering than non-Hispanic whites (21); increased arterial stiffness in African Americans (9) |
| Pioglitazone                  | Improved β-cell function and insulin secretion and suppressed gluconeogenesis in Mexican Americans (22) |
| Rosiglitzazole                | Increased hepatic insulin extraction and improved glycemic control in African Americans with impaired glucose tolerance and type 2 diabetes (23) |
| Nateglinide                   | There is one publication on the use of this drug in Asian patients, but no A1C data were reported. (8)        |
| Repaglinide                   | There is one publication on the use of this drug in Asian patients, but no A1C data were reported. (8)        |
| Exenatide                     | A1C reductions reported in Asians (24)                                                                      |
| Liraglutide                   | A1C reductions reported in Asians (25)                                                                      |
| Lixisenatide                  | A1C reductions reported in Asians with diabetes ineffectively controlled with insulin or metformin ± a sulfonylurea (26) |
| Dapagliflozin                 | A1C reductions of 0.41–0.45% in Asians (27)                                                                |
| Empagliflozin                 | Studied in African-American and Asian populations, but no data on A1C reduction were reported (28)          |
| Colesevelam                   | Tested in Hispanic patients, but no data on A1C reduction were reported (8)                                  |

| TABLE 3. Drugs Tested in All Three Racial/Ethnic Groups |
|---------------------------------|----------------------------------------------------------|
| Medication                      | Percentage of Studies That Included:                    |
|                                 | African-American Subjects | Hispanic Subjects | Asian Subjects |
| Sulfonylureas                   | 31                         | 39               | 33            |
| Miglitol                        | 44                         | 49               | 6             |
| Metformin                       | 19                         | 15               | 19            |
| Rosiglitazone                   | 12                         | 13               | 2.9           |

CLINICAL DIABETES JOURNALS.ORG
increased health care costs, and possibly deaths.

The authors of this article had numerous industry relationships to disclose, including writing services from a drug company–paid writer and drug company review of the manuscript before submission. Such potential conflicts of interest can be problematic in that they open the article up to possible industry bias. We applaud the authors for disclosing their conflicts of interest, but at the same time, we must caution readers about the information presented in this article, as well as the information that may have been omitted. There is good comparative efficacy research being done at the Agency for Healthcare Research and Quality that may be of use in conjunction with this article to further elucidate disparities in care and provide additional information on the efficacy of diabetes medications in Asian, Black, Latino, and Native American populations.

Duality of Interest
No potential conflicts of interest relevant to this article were reported.

References
1. Centers for Disease Control and Prevention. Age-adjusted hospital discharge rates for diabetes as any-listed diagnosis per 1000 diabetic population, by race, United States, 1988–2009. Available from http://www.cdc.gov/diabetes/statistics/dmany/fig6.htm. Accessed 11 September 2015
2. Bulger JB, Shubrook JH, Snow R. Racial disparities in African Americans with diabetes: process and outcome mismatch. Am J Manag Care. 2012;18:407–413
3. Okosun IS, Annon F, Dawodu EA, Eriksen MP. Clustering of cardiometabolic risk factors and risk of elevated HbA1c in non-Hispanic White, non-Hispanic Black and Mexican-American adults with type 2 diabetes. Diabetes Metab Syndr 2014;8:75–81
4. Mathieu RA, Powell-Wiley TM, Ayers CR, et al. Physical activity participation, health perceptions, and cardiovascular disease mortality in a multiethnic population: the Dallas Heart Study. Am Heart J 2012;163:1037–1040
5. Centers for Disease Control and Prevention. Percentage of adults aged 18 years or older with diagnosed diabetes receiving a dilated eye exam in the last year, by race/ethnicity, United States, 1994–2010. Available from http://www.cdc.gov/diabetes/statistics/preventive/tneweeyeexrace.htm. Accessed 11 September 2015
6. Kirk JK, D’Agostino RB, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2006;29:2130–2136
7. Piccolo RS, Pearce N, Araujo AB, McKinlay JB. The contribution of biogeographical ancestry and socioeconomic status to racial/ethnic disparities in type 2 diabetes mellitus: results from the Boston Area Community Health Survey. Ann Epidemiol 2014;24:648–654, 654.e641
8. Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin 2015;31:913–923
9. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long-term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005;91:589–594
10. Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonlureas. J Diabetes Complications 2003;17:179–185
11. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12:613–622
12. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998;21:416–422
13. Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998;21:409–415
14. Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glyemic control in Chinese patients with type 2 diabetes. J Diabetes 2012;4:227–237
15. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106–116
16. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012;28:268–275
17. Davidson JA, Lajara R, Aguilar RB, Mattheus M, Woerle HJ, von Eynatten M. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. BMJ Open Diabetes Res Care 2014;2:e000020
18. Thrasher J, Daniels K, Patel S, Whettenjy C, Woerle HJ. Efficacy and safety of pioglitazone in black/African American patients with type 2 diabetes: a 6-month, randomized, double-blind, placebo-controlled study. Endocr Pract 2014;20:412–420
19. Pan C, Xing X, Han P, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:737–744
20. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27(Suppl. 3):21–29
21. Williams LK, Padlukasaharasm B, Ahmedani BK, et al. Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 2014;99:3160–3168
22. Glass LC, Cusi K, Berria R, et al. Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with type 2 diabetes: a double tracer OGTt study. Clin Endocrinol (Oxf) 2010;73:339–345
23. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin
24. Schwartz SL, Ratner RE, Kim DD, et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008;30:858–867

25. Suzuki D, Toyoda M, Kimura M, et al. Effects of lixisenatide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. Intern Med 2013;52:1029–1034

26. Yu Pan C, Han P, Liu X, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulphonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev 2014;30:726–735

27. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 2014;16:1102–1110

28. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147–158

29. Rodriguez JE, Campbell KM, Adelson WJ. Poor representation of blacks, Latinos, and Native Americans in medicine. Fam Med 2015;47:259–263

30. Betancourt JR, King RK. Unequal Treatment: the Institute of Medicine report and its public health implications. Public Health Rep 2003;118:287–292

31. Betancourt JR, Maina AW, Soni SM. The IOM report Unequal Treatment: lessons for clinical practice. Del Med J 2005;77:339–348

32. Publix. Free medication program. Available from http://www.publix.com/pharmacy-wellness/pharmacy/pharmacy-services/free-medication-program. Accessed 17 September 2015